A specific fat-distribution condition
The established use concerns excess visceral fat in adults with HIV-associated lipodystrophy. It should not be generalized to anyone who wants a smaller waist.
Illustrative packaging. Final product may differ.
Peptides
Tesamorelin
Peptide option
Get a clearer picture of tesamorelin and its specific uses. Explore who it is for and why it is not a general weight-loss treatment.
Availability to be confirmed
Uses & evidence at a glance
- An approved tesamorelin product reduces excess abdominal fat in adults with HIV-associated lipodystrophy.
- It is not a general weight-loss treatment; compounded versions are not FDA-approved.
Labs are required for this catalog option. A clinician determines the evaluation needed.
For prescribed peptide self-injection only, not Botox or IVs. Take your first dose with Christina’s guidance and learn to continue at home, when clinically appropriate. NYC appointments are priced and scheduled separately. No training fee is charged at checkout.
Meet Christina and explore training →Pricing coming soon. Get updates
Payment requests an initial order. Clinical approval is required before fulfillment.
Read the evidence for Tesamorelin ↗THE PLAIN-LANGUAGE GUIDE
What does Tesamorelin do?
Tesamorelin stimulates growth-hormone release. An FDA-approved product containing it, Egrifta WR, reduces excess abdominal fat in adults with HIV-associated lipodystrophy, a specific condition affecting fat distribution.
That benefit applies to the approved product and diagnosed population. This compounded catalog option is not FDA-approved, and tesamorelin is not a general weight-loss treatment.
Hormone pathway
Tesamorelin acts through growth-hormone signaling and raises IGF-1. It works differently from GLP-1 medicines that act on appetite pathways.
Monitoring matters
Clinicians monitor response and laboratory findings. Elevated IGF-1 and changes in blood glucose are important considerations, not just a routine lab checkbox.
Does reducing abdominal fat mean losing weight?
Not necessarily. A change in visceral fat is different from overall weight loss. The approved labeling specifically says tesamorelin is not indicated for weight-loss management.
Explore the evidence for Tesamorelin →Safety and suitability: what to discuss
The approved label lists contraindications including active cancer, disruption of the pituitary axis, and pregnancy. Risks include glucose intolerance, fluid retention, and hypersensitivity. Discuss the complete prescribing information with your clinician.
A clinician needs to review your medical history, medicines, and goals. This page does not establish suitability or give instructions for dosing or combining treatments.
Sources and further reading
DIVE DEEPER
Learn more about Tesamorelin.
Hormone-related therapies
Sermorelin vs tesamorelin: uses, approval, and questions to ask
Understand tesamorelin’s specific approved use, sermorelin’s history, and why hormone-related peptide claims need careful context.
Read the guide Reading the evidencePeptide therapy claims: how to check what the evidence supports
Learn to check peptide claims against the exact product, human evidence, intended use, and approval status. A practical checklist for comparing online information.
Read the guide The care processHow to prepare for telehealth medical intake
Use this practical checklist for online medical intake: health information, questions, privacy, follow-up, and the difference between checkout and clinical review.
Read the guideAN INFORMED NEXT STEP
Start with understanding.
Look at the evidence for the exact formulation and intended use before making a decision.
- Explore the evidence. Read the guide below, including the limits of current research.
- Know the full details. Confirm formulation, availability in your state, and the complete cost.
- Discuss with a clinician. Review your goals and medical history before any treatment decision.
BEFORE YOU DECIDE
Common questions.
What does Tesamorelin do?
Get a clearer picture of tesamorelin and its specific uses. Explore who it is for and why it is not a general weight-loss treatment. An approved tesamorelin product reduces excess abdominal fat in adults with HIV-associated lipodystrophy. It is not a general weight-loss treatment; compounded versions are not FDA-approved.
Can I order Tesamorelin through Toven now?
This option does not currently have a confirmed price and cannot be added to checkout. Contact our team for availability updates.
What will it cost?
Pricing for this option is being confirmed. No payment is required to join the interest list.
How do I know if it is appropriate for me?
A licensed clinician must assess your health history, current medications, and treatment goals. A quiz result or catalog listing cannot establish suitability. Do not combine options based on this catalog.
Educational information, not personal medical advice. Compounded medications are not FDA-approved. A catalog listing does not establish safety, effectiveness, or availability. Formulation, location, pharmacy requirements, and independent clinical review determine access.